Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06609304
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-28
Brief Title:
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prospective Clinical Study of Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
axi-cel
Brief Summary:
The goal of this clinical trial is to learn if Axicabtagene Ciloleucel axi-cel works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma LBCL It will also learn about the safety of axi-cel treatment The main questions it aims to answer are
Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment
What medical problems do participants have when receiving axi-cel treatment
In this investigator-initiated single-arm clinical trial participants will
Receive atezolizumab treatment at 20106 cellsKg as a one-time therapy
Visit the clinic as instructed for checkups and tests
Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment
What medical problems do participants have when receiving axi-cel treatment
In this investigator-initiated single-arm clinical trial participants will
Receive atezolizumab treatment at 20106 cellsKg as a one-time therapy
Visit the clinic as instructed for checkups and tests
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None